ArticleJournal of experimental & clinical cancer research : CR2024

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.

Eric A Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.